Agatston score | CACSP based on age, gender and ethnicity | |||||
---|---|---|---|---|---|---|
Parameter | Effect estimate* (SE) | p Value | Model R^{2} | Effect Estimate* (SE) | p Value | Model R^{2} |
Age (per 10 years) | 4.67 (1.18) | <0.001 | 0.242 | 0.88 (1.02) | <0.001 | 0.153 |
Women | 0.51 (1.27) | 0.005 | 1.20 (1.03) | <0.001 | ||
Pack-years (per 20 years) | 1.22 (1.09) | 0.026 | 0.99 (1.01) | 0.320 | ||
FEV_{1}% predicted (post bronchodilator) (per 10%) | 0.85 (1.08) | 0.029 | 1.01 (1.01) | 0.590 | ||
CVD | 2.37 (1.25) | <0.001 | 1.06 (1.03) | 0.046 | ||
6MWD (per 100 m) | 1.00 (1.10) | 0.990 | 0.97 (1.01) | 0.017 | ||
IL-6 (per 1 SD) | 0.99 (1.11) | 0.953 | 1.02 (1.02) | 0.221 | ||
Clara cell protein (per 1 SD) | 1.01 (1.12) | 0.951 | 1.02 (1.02) | 0.132 | ||
Surfactant protein D (per 1 SD) | 1.15 (1.12) | 0.199 | 1.02 (1.02) | 0.177 |
*The effect estimate represents the change in score per 1 unit change in the parameter after adjusting for all other terms in the model. Note: the dependent variables (Agatston score and CACSP) were log transformed in this multiple regression model and the exponentiated values of the coefficients and SEs are provided here. For example, a coefficient of 2.37 for CVD corresponds to a 137% higher Agatston score for those with CVD compared with those without, when all other predictors are held fixed.
6MWD, 6 min walking distance; CVD, cardiovascular disease; IL-6, interleukin 6.